Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.

Literature DB >> 11168096

In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.

C Edlund¹, C E Nord.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2000 PMID： 11168096 DOI： 10.1046/j.1469-0691.2000.00034-6.x

Source DB: PubMed Journal: Clin Microbiol Infect ISSN： 1198-743X Impact factor: 8.067

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

1. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2006-08-28 Impact factor: 5.191

Review 2. Tigecycline.

Authors: James E Frampton; Monique P Curran
Journal: Drugs Date: 2005 Impact factor: 9.546

3. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.

Authors: E J Goldstein; D M Citron; C V Merriam; Y Warren; K Tyrrell
Journal: Antimicrob Agents Chemother Date: 2000-10 Impact factor: 5.191

4. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.

Authors: Gopal Muralidharan; Richard J Fruncillo; Marlynne Micalizzi; Donald G Raible; Steven M Troy
Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191

5. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.

Authors: Patricia A Bradford; Peter J Petersen; Mairead Young; C Hal Jones; Mark Tischler; John O'Connell
Journal: Antimicrob Agents Chemother Date: 2005-09 Impact factor: 5.191

10. Therapeutic Drug Monitoring of Tigecycline in 67 Infected Patients and a Population Pharmacokinetics/Microbiological Evaluation of A. baumannii Study.

Authors: Tianli Yang; Hekun Mei; Jin Wang; Yun Cai
Journal: Front Microbiol Date: 2021-06-16 Impact factor: 5.640

In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.

1. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.

Review 2. Tigecycline.

3. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.

4. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.

5. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.

6. Effect of tigecycline on normal oropharyngeal and intestinal microflora.

7. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.

Review 8. The glycylcyclines: a comparative review with the tetracyclines.

9. In vitro activities of tigecycline against the Bacteroides fragilis group.

10. Therapeutic Drug Monitoring of Tigecycline in 67 Infected Patients and a Population Pharmacokinetics/Microbiological Evaluation of A. baumannii Study.